SyneuRx is currently conducting clinical development of two COVID-19 treatments— Pentarlandir® in oral capsule form and Airnecflu® in an inhaled form. Pentarlandir® began US Phase 2 clinical trial following FDA IND approval in Q2 2021 (click here for trial information: NCT04911777). The Phase 3 study is expected to be launched in 2022 as a global multi-center clinical trial. First-in-human study for Airnecflu® is expected to launch in H1 2022.
SyneuRx is a clinical-stage global biotech company, which is currently conducting clinical development of new classes of drugs for COVID-19 as well as multiple major CNS (Central Nervous System) disease conditions. We have several early and late phase clinical trials currently in progress.
SyneuRx is pioneering and developing revolutionary, completely new classes of drugs to answer the unmet medical needs in central nervous system (CNS) disorders. Our candidate drugs hold great promise to expedite the development process and reach a leading position in the CNS drug market quickly.
SyneuRx was founded in 2013 with the goal of using scientific breakthroughs to develop novel CNS drugs for patients suffering from severe mental/behavioral health issues. The multi-national team is located in both the US and Taiwan.
The innovations, resources, and production from both the US and Asia provide the strength of our team. Our experienced team has developed and tested multiple candidate drugs and bring exceptional technical expertise as well as business experience to the drug development process, enabling the launch of the company's patented new drugs in a rapid and efficient manner.
With more than 100 peer-reviewed articles published and more than fourteen thousand citations, Guochuan Emil Tsai, founder and CEO of SyneuRx and Professor at the Department of Psychiatry and Behavioral Sciences at the University of California, Los Angeles (UCLA), is an internationally renowned scientist in neurosciences and brain disorders, whose main area of focus is modulating the NMDA system.
Professor Guochuan Emil Tsai is the first scientist to report the therapeutic efficacy of N-methyl- D-aspartate (NMDA) receptors enhancement for a wide variety of CNS disorders; setting the tone for a novel line of neurological treatments. As CEO of SyneuRx, he provides an overview of the company’s extremely promising R&D pipeline and the seven groundbreaking CNS investigational treatments, two of which have already been granted Breakthrough Therapy Designations by the US FDA.
SyneuRx is a global biotech company listed in Taiwan (TWSE: 6575), undergoing clinical development of new classes of drugs for multiple major CNS conditions and respiratory viral diseases like COVID-19.
Several early and late phase clinical trials are currently in progress for multiple indications globally, including schizophrenia, dementia, depression, and COVID-19.
SyneuRx is currently conducting clinical development of two COVID-19 treatments— Pentarlandir® as an oral capsule and Airnecflu® as an inhaled treatment.
Pentarlandir® began US Phase 2 clinical trial following FDA IND approval in Q2, 2021 (click here for trial information). The phase 3 study is expected to launch in 2022 as a global multi-center clinical trial.
Pentarlandir® is intended to treat COVID-19 patients with mild symptoms within 96 hours of diagnosis confirmed by a positive PCR test, thus allowing patients to administer the medication at home early in the course with the goal to reduce/avoid disease progression and the need of hospitalization or quarantine. Essentially, Pentarlandir® can be to COVID-19 what Tamiflu is to flu and can fill the void arising from unequal distribution of vaccines, low vaccination rates, and inconsistent vaccine efficacies. If successfully developed, it will lessen the burdens on patients, their family, and friends, and on the international healthcare system as a whole.
Both Pentarlandir® and Pfizer’s PAXLOVID™ are designed in oral formulation, have the same mechanism of action working against the main protease (Mpro) of SARS-CoV-2, and carry the potential in inhibiting SARS-CoV-2 variants. To date, SyneuRx and Pfizer are the only two companies whose experimental Mpro inhibitors are in human testing. Pentarlandir® has demonstrated a high level of safety. SyneuRx’ preclinical work has shown that Pentarlandir® can work against SARS-CoV-2 in 3 ways:
In addition, Pentarlandir® is shown to inhibit H1N1 replication as well, thus holding the promise to be a powerful tool for “twindemic,” which is expected when a wave of influenza (flu) and a surge of COVID-19 strike at the same time.
Pentarlandir® is also a D-amino acid oxidase (DAAO) inhibitor, which modulates N-methyl-D-aspartate (NMDA) receptors and protects neurons in human brains. Therefore, Pentarlandir® can potentially improve the common post-COVID-19 conditions such as depression and cognitive deterioration.
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir®
Has Entered Final Portion of FDA Phase II Testing
Based on Highly-Purified Isomers of Tannic Acid and Acting as a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir Has Shown Significant Anti-Viral Properties
with Minimal Observed Side Effects
November 19, 2021 – Los Angeles, CA – SyneuRx™ International, (www.syneurx.com), a pioneering developer of novel CNS (Central Nervous System) and anti-viral pharmaceuticals, today announced that its investigational oral SARS-CoV-2 (COVID-19) anti-viral drug candidate Pentarlandir® has successfully been in Phase II US-FDA trial for several months and is nearing Phase III in 2022.
Designed as an early-stage COVID-19 treatment, Pentarlandir® is given by mouth to patients suffering either from ‘breakthrough’ cases of COVID-19 (for those who have been previously vaccinated or infected) or potentially as a first-line treatment pathway for the unvaccinated who might otherwise face potential hospitalization and death. SyneuRx has previously received ‘Breakthrough Therapy Designation and Orphan Drug Designation’ grants by the FDA for its CNS drug candidates.
Pentarlandir® is based on highly-purified isomers of tannic acid and is derived from a botanical origin (just like Tamiflu®, which is itself purified from a chemical found in Star Anise). Pentarlandir® specifically targets main protease, or 3CL-protease, which turns baseline viral protein into the necessary building blocks that enable the replication of new viral particles and also inhibits TMPRSS2 for viral entry. Pentarlandir acts on not just the serine protease TMPRSS2, but also HAT (both of which are critical for the entry of influenza-type viruses into cells). Therefore, it holds promise as a therapeutic tool for ‘twindemic’ scenarios (treatment of both COVID-19 and Influenza endemics).
If successfully developed, SyneuRx intends to make Pentarlandir® available to the world’s developing nations as part of the United Nations-backed Medicines Patent Pool. Pentarlandir® is projected to be widely-available worldwide within 12-24 months following phase III under current factory availability.
More information about the Pentarlandir Phase II trial can be found here: https://www.clinicaltrials.gov/ct2/show/NCT04911777
How was Pentarlandir® Discovered?
After years of research into how several debilitating CNS diseases operate, SyneuRx scientists arrived at the theory that metabolizing/regulating enzymes such as protease were in fact a critically-important ‘drug target’ for these types of illnesses, which coincidentally have proven to be a critical mechanism of action for several virally-caused diseases such as HIV and Hepatitis.
Researchers decided to test all the compounds in the company’s patent portfolio against the SARS-CoV-2 protease and found to their surprise that several SyneuRx-developed compounds were potent protease blockers for both SARS-CoV-2 and H1N1 influenza viruses, of which the compound that became Pentarlandir proved to be the most efficacious.
Further studies confirmed Pentarlandir®’s ability to block coronavirus replication in multiple, rigorous cellular studies and it also proved to maintain an excellent safety profile, which made it the best candidate to go into clinical development.
“The importance of finding a safe, inexpensive and highly-efficacious oral drug capable of treating COVID-19 for people regardless of their risk of progression cannot be overstated,” said Dr. Guochuan ‘Emil’ Tsai MD PhD MAS, founder and CEO of SyneuRx. “Our researchers have devoted several years to the discovery, isolation and development of Pentarlandir and we are very pleased with the progress of the Phase II trial. We are actively developing this candidate drug and remain hopeful that we will continue our positive track record to date.”
SyneuRx was founded in 2013 with the goal of using scientific breakthroughs to develop novel CNS drugs for patients suffering from severe mental health disorders. The multi-national team is located in the U.S. and Taiwan. Prior to starting SyneuRx, Dr. Guochuan (Emil) Tsai, MD, PhD was a member of the faculty at Harvard Medical School and is now at the UCLA School of Medicine, Department of Psychiatry and Biobehavioral Sciences.
SyneurRx and Pentarlandir are trademarks and registered trademarks, respectively, of SyneuRx International. All previous trademarks and registered trademarks previously cited are hereby recognized and acknowledged.
The information contained in this release is as of November 18, 2021. SyneuRx assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about SyneuRx’s efforts to combat COVID-19 as well as flu and the company’s investigational oral antiviral candidate Pentarlandir® (including qualitative assessments of available data, potential benefits, expectations for clinical trials, advanced purchase agreements, the anticipated timing of data readouts, regulatory submissions, regulatory approvals or authorizations, planned investment and anticipated manufacturing, distribution and supply), involving substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the ability to produce comparable clinical or other results including efficacy, safety and tolerability profile observed to date, in additional studies or in larger, more diverse populations following commercialization; the risk that preclinical and clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when any drug applications or submissions to request emergency use or conditional marketing authorization for any potential indications for Pentarlandir may be filed in any jurisdictions and if obtained, whether or when such emergency use authorization or licenses will expire or terminate; whether and when regulatory authorities in any jurisdictions may approve any such applications for Pentarlandir, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling or marketing, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of Pentarlandir, including development of products or therapies by other companies; risks related to the availability of raw materials for Pentarlandir; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or maintain access to logistics or supply channels commensurate with global demand, which would negatively impact our ability to supply the estimated numbers of courses of Pentarlandir within the projected time periods; whether and when additional purchase agreements will be reached; the risk that demand for any products may be reduced or no longer exist; uncertainties regarding the impact of COVID-19 on SyneuRx’s business, operations and financial results; and competitive developments.
In the early 2000’s, SyneuRx founder and CEO Dr. Guochuan (Emil) Tsai, MD, PhD, MAS was evaluating a series of prominent new neurological pathways he had discovered while at Harvard and UCLA that showed a profound impact on patients suffering from depression, dementia and schizophrenia.
After several years of research into pharmacologically-active chemicals that might impact these novel regulatory pathways, several biologically-active agents proved to be very promising drug candidates affecting these newly-found pathways, producing very positive results in early animal and human trials.
In 2013, Dr. Tsai founded SyneuRx in Taipei, Taiwan to facilitate commercial development of these and other Central Nervous System (CNS) pharmaceuticals he was developing - the company was listed on the Taiwan Stock Exchange shortly thereafter.
Prior to starting SyneuRx, Dr. Guochuan (Emil) Tsai, MD, PhD, MAS was a member of the faculty at Harvard Medical School - he is now at the UCLA School of Medicine, Department of Psychiatry and Biobehavioral Sciences. His expertise in brain science, psychiatry and management began with a rigorous academic background, including his education at National Yang-Ming University, Taiwan, Johns Hopkins Medical School and Carey School of Business (both of Baltimore, Maryland).
Dr. Tsai trained in his formative clinician years at Massachusetts General Hospital, McLean Hospital, and the teaching hospitals of Harvard. He has received advanced degrees in general psychiatry and child / adolescent psychiatry as well as neuroscience, and is a diplomate of the American Board of Psychiatry and Neurology in both adult and child psychiatry. He has been elected to receive the title of ‘Fellow’ at the esteemed American College of Neuropsychopharmacology and is a member of the Society for Neuroscience.
He has published more than 100 scientific articles, with 14,000 citations as well as holding more than 100 granted patents. His pioneering research opened up the field of glutamatergic treatments for brain disorders; he was the first to report the therapeutic efficacy of NMDA modulation for a wide variety of CNS disorders.
The new therapeutic classes he validated include: full and partial agonists of NMDA receptor, inhibitors for glycine transporter and D-amino acid oxidase inhibitor. These discoveries are the cornerstone that led to the establishment of the pharmaceutical venture SyneuRx (TT6575) - founded by Dr. Tsai in 2013, and which has a diverse pipeline of CNS and anti-viral therapeutics.
Most recently, Dr. Tsai has discovered an array of novel chemicals that are inhibitors of 3CL protease, a pathway that is absolutely needed for the processing of SARS-CoV-2 (COVID-19) viral proteins during viral replication, and inhibitors of TMPRSS2 for viral entry. In other words, it was found that the most promising of these new drug candidates stops the COVID-19 virus from multiplying as well as entering human cells.
SyneuRx is currently traded on the Taipei Exchange, with a ticker ID of TT6575. A complete 5-year stock history of the company since December 01, 2016 may be found at https://finance.yahoo.com/quote/6575.TWO/
Ongoing R&D is undertaken in Taipei at 20F-10, No.99, Sec.1, Xintai 5th Rd, Xizhi Dist., New Taipei City 22175, Taiwan, while the United States operation is responsible for clinical trials, sales and marketing and is based at 411 Amapola Ave. Torrance, CA 90501.
SyneuRx employs 52 people worldwide.
SyneuRx currently has two schizophrenia drug candidates under FDA evaluation (two Breakthrough Therapy Designations granted by US-FDA for adult and treatment-resistant schizophrenia); two drug candidates under FDA evaluation for depression and suicide, two drug candidates under FDA evaluation for dementia, and two for COVID-19 treatments (the COVID drug Pentarlandir® has both oral and inhaler formulations for this modality).
Currently, SyneuRx has not received FDA approval for its pharmacological products in the pipeline, as they are all in Phase II or III testing at the moment. It is worth noting that the FDA approves only 20-60 new drugs a year for all diseases combined and the process is understandably painstaking to protect public health.
The company currently employs 10 PHD’s/MD’s in biochemistry, molecular biology, neuroscience, pharmacology, veterinary medicine, medicine, and health economics.
From a methodology standpoint, SyneuRx starts with compound discovery (invention) of novel mechanisms for therapeutic treatments satisfying both CNS and anti-virologic use-cases, then goes on to validation of these novel mechanisms, to involvement in a wide range of preclinical studies all the way through to clinical studies, manufacturing, marketing and distribution.
Unless you are involved in any of our FDA trials or are a clinical / research mental health scientist, there is no reason to be familiar with our company as SyneuRx has no consumer-available drugs for sale at the moment.
SyneuRx has received several ‘Breakthrough Therapy Designations and Orphan Drug Designations’ granted by the FDA. However, that dossier has not yet been made public by the Agency.
There are 7 other investigational drugs, see the drug pipeline on www.syneurx.com for more information about our potential therapies for depression, dementia and schizophrenia.
We have two Breakthrough Therapy Designations by the FDA. They are now in late-phase clinical development, but are not approved as of yet.
Working through years of research into how several debilitating CNS diseases operate, SyneuRx scientists arrived at the theory that regulatory enzymes such as protease would be a critically-important ‘drug target’ for these types of illnesses, which coincidentally is also a target for several virally-caused diseases such as HIV and hepatitis.
Researchers decided to test all the compounds in the company’s patent portfolio against protease and found to their shock that several SyneuRx-developed compounds were potent protease blockers, of which the compound that became Pentarlandir® proved to be the most safe and efficacious.
We confirmed its ability to block coronavirus replication in multiple, rigorous cellular studies and it also proved to maintain an excellent safety profile, which made Pentarlandir® the best candidate to go into clinical development.
Pentarlandir is based on isomers of tannic acid, which are derived from a botanical origin (Tamiflu®, by way of comparison, is itself purified from Star Anise) - SyneuRx purifies the specific isomers of tannic acid to ~99% from a high-content source plant.
No, there is a huge difference between tannins and tannic acid. Tannic acid is not present in tea or red wine at all, these contain tannins OTHER than tannic acid. Tannins are a broad class of compounds that are present in foods and beverages alike. Tannic acids, however, are a diverse group of compounds with wildly-divergent potencies vis a vis stopping the COVID-19 virus replication.
Drug development is about identifying the ‘right’ target (mechanism of action) and finding the safest and most effective compounds to address that specific target. Protease proved to be the right target to prevent the COVID-19 virus from replicating in cells or animals, so the next step was to find the right compound at the right dose that was most efficacious for human patients.
Many promising COVID-19 drugs are essentially ‘fishing expeditions’ trying to find the right path to safety and efficacy - virtually all of these types of drugs fail to be approved. Untenable side effects and failure to show categoric proof of efficacy via statistical norms are other reasons why so many previous drug candidates have failed even in Phase II or III FDA drug trials.
SyneuRx has found Pentarlandir® also blocks replication of the H1N1 influenza virus in cellular assay – we continue to test the efficacy of Pentarlandir® against H1N1 and other potentially lethal viral strains.
Pentarlandir® specifically targets the Main protease, or named 3CL-protease, which turns baseline viral proteins into the necessary building blocks that enable the virus to replicate new viral particles.
No. Vaccines induce the body to create antibodies which prevent people from getting sick in the first place. Pentarlandir® is indicated for use in already infected COVID-19 patients and acts to inhibit viral reproduction - it is therefore a treatment, not a preventive vaccine.
ABSOLUTELY NOT - vaccines are for prevention, while Pentarlandir® is designed solely for treatment of existing COVID-19 illness. Vaccination is always preferable to treatment in non-infected individuals, without exception!
Until the entire world has been vaccinated, there is a huge need for an antiviral drug like Pentarlandir® - and even after 95%+ world vaccination rates, the virus will continue to mutate at an unpredictable rate. As such, current vaccines may prove to be tragically and immediately ineffective if facing a major mutation (called immune evasion), at least until a new version of the vaccine can be created and approved for use. This process alone can take several months (at the least) and thus a convenient, safe and effective treatment for cases involving the new mutation is warranted for stockpiling and eventual distribution.
Though Airnecflu® has the same active ingredient as Pentarlandir®, it is designed for inhalation use only.
Due to the immediate urgency of the COVID pandemic, the CNS label will be sought after the initial indication of efficacy against COVID-19.
Please refer to NCT04911777 at clinictrials.gov.
For the ongoing Phase II study, the study individuals need to have symptomatic and documented mild COVID-19 disease. The purpose of the study is to determine Pentarlandir®’s efficacy in resolving the symptoms and slowing down or stopping the progression of mild to moderate COVID-19 into a severe illness in a range of test subjects.
Pentarlandir® is currently in Phase II trials as of November, 2021. The FDA approved the study to proceed in the early summer of 2021.
Not as of yet.
In the Phase II study, the drug is administered for 14 days – that number could move down in Phase III if it is determined to be safe and effective to lower the dosage period.
Final guidelines on Pentarlandir® treatments will be provided by your physician if the drug is approved for treating COVID.
Please refer to the public information regarding the trial at NCT04911777 in clinicaltrials.gov.
Please visit the SyneuRx website at www.syneurx.com.
There have been no serious side effects observed to date as part of the Phase II Pentarlandir® clinical trial. We continue to monitor the safety of our test subjects throughout the clinical studies. For Airnecflu®, we are now conducting a GLP animal toxicity study for potential inhalation side effects. It will be completed by Q2, 2022.
No, they have completely different mechanisms of action and neither of these drugs is in fact proven to work against COVID-19 at all.
The initial report touting Ivermectin as an effective COVID-19 cure was found to be fraudulent. There is also no scientifically-valid evidence supporting the efficacy of hydroxychloroquine as a COVID-19 treatment or cure.
Pentarlandir® serves a different population than Pfizer’s Paxlovid™ or Merck’s Molnupiravir™. Paxlovid and Molnupiravir were both tested on a similar population – unvaccinated COVID patients with high risks of progressing to severe COVID – and both are found to reduce the risks of hospitalization or death (89% by Paxlovid and 50% by Molnupiravir). While these two new drugs are potentially effective to high-risk COVID patients, there is still no treatment for those who are not high-risks.
Our investigational drug Pentarlandir® is aimed to treat everyone, vaccinated or not, early in the process with mild-to-moderate symptoms and without high risks of developing severe COVID. This is a much wider indication and will be applicable to most patients.
Pentarlandir® has 3 pathways to suppress COVID virus infection. The main mechanism of action is the same as the more effective Pfizer’s Paxlovid™, which is to inhibit the main-protease of SARS-CoV-2 from producing the necessary building blocks for the virus to replicate. In addition, Pentarlandir® can also inhibit TMPRSS2 and blocks the viral entry to human cells. Last but not least, it can also work to suppress cytokines to reduce serious complications such as a cytokine storm from COVID.
Pentarlandir® acts on not only the serine protease TMPRSS2 (transmembrane protease serine 2) but also HAT (human trypsin-like protease), both of which are critical for the entry of influenza-type viruses into cells.
Therefore, Pentarlandir® and its next generation product Airnecflu® (for inhalation use) hold promise to be the therapeutic tool for ‘twindemic’ scenarios (treatment of both COVID-19 and Influenza endemics).
While Roche’s antiviral targets the same patient population (mild-to-moderate COVID patients), it has completely different mechanisms of action: AT-527 inhibits viral replication via RdRp chain termination and NiRAN inhibition. If anything, At-527 is closer to Remdesivir than to our candidate drug Pentarlandir®. Cumulative evidence from clinical studies to date have shown little-to-no benefit of Remdisivir for hospitalized patients with COVID (review article in NEJM Aug 3, 2021) and the WHO has recommended against the use of Remdesivir due to limited clinical benefits.
Current tests around fluvoxamine are still inconclusive at best, but we are watching its progress carefully and hope that it does prove to be an effective COVID-19 treatment in addition to Pentarlandir®.
No, Tamiflu acts on neuraminidase – Airnecflu® operates via serine protease inhibition. Tamiflu is totally ineffective against COVID-19 because of the type of pathways this virus uses for entry of the cell and replication.
No, Pentarlandir® acts on the serine proteases TMPRSS2 and HAT, which are critical for the entry of influenza-type viruses and SARS-coronavirus into cells. Tamiflu does not and is thus ineffective against COVID-19. Both Pentarlandir® and Airnecflu® do share one important similarity to Tamiflu – all three originally are derived exclusively from common organic sources.
Absolutely! The world is in a pandemic and profits must never replace human lives, in the opinion of SyneuRx management.
Availability will be determined by the approval of national regulatory agencies such as the U.S. FDA. The FDA is the world’s gold standard for drug approvals - most countries are expected to swiftly follow suit if the FDA approves Pentarlandir®.
At our current single factory capacity – 2,000,000. Should large pharmaceutical companies with multiple factories worldwide choose to partner with SyneuRx, that number could easily increase to 100X that number.
No, but it will be affordable - Pentarlandir® was created to save humanity from viral catastrophe, not for business gain. We will make Pentarlandir® as accessible as possible worldwide for those who need it after the drug is approved.
We currently have no such partnerships in place but are keenly interested in forming them to maximize availability of our investigational COVID-19 treatment to the world.
Airnecflu® is indicated for patients with primary respiratory infections, which is how most COVID patients present before hospitalization. There is no restriction for using either version of the drug, but if patients have infections in other organ systems outside of the lungs, we would recommend the oral Pentarlandir® instead. The final instructions will be from your physician once the drugs are approved.
SyneuRx has a proprietary manufacturing process. Other than the badly-broken worldwide supply chain experienced by any company in 2021 requiring raw materials or finished goods from another part of the world, the answer is no.
We are still determining the best way to move forward for this.
After Phase II has been marked as completed by the FDA, the next step is to progress to a Phase III FDA study and final review by a Board of specialist physicians and scientists who will make their recommendations to the Agency for final decision.
If everything goes forward in a positive manner, Pentarlandir® is projected to be widely available worldwide within 12-24 months from November of 2021, while Airnecflu® is projected to be widely available in 2023-2024. Should a major pharmacology company partner with SyneuRx to speed up the clinical development, manufacture and distribution, those times-to-market would be massively reduced.
Protease inhibitors have proven themselves over decades of use to become the main therapeutic agent treating infections caused by other single strand RNA viruses. Proven science - not hype - drives our potential COVID-19 efficacy claims.
As a publicly-traded company, we cannot make any comment in regards to forward-looking statements outside of officially-sanctioned analyst calls.
As a public company for several years that has been listed in Taipei, SyneuRx (like other public companies) regularly undergoes official regulation and exhaustive auditing by both the Exchange and the Taiwanese governmental agencies. The founder/CEO of the company is an internationally-recognized scientist and physician with impeccable academic and medical credentials.
Our announcement is all about communicating that a potential COVID therapy with solid MOA (mechanism of action) is under development that can save lives in a global pandemic. A pandemic that desperately needs treatments for a lethal disease possessed of high transmissibility - the idea of using this announcement for personal gain is repugnant to the company founders, the Board of Directors and all the major stockholders.
Further, the stock market in Taipei is under constant scrutiny by government agencies and ‘insiders’ cannot trade stock around the time of any major announcement until an appropriate window of delay after the news has passed.